AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $5.50 for the company and are predicting that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 85 out of 255 based on the ratings given to related companies.
Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of AEterna Zentaris in a report on Thursday, August 15th. TheStreet cut shares of AEterna Zentaris from a “c-” rating to a “d” rating in a research note on Thursday, June 13th. ValuEngine cut shares of AEterna Zentaris from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. Finally, Zacks Investment Research raised shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Tuesday.
AEZS stock traded down $0.02 during mid-day trading on Friday, hitting $0.90. 78,584 shares of the company were exchanged, compared to its average volume of 232,458. The business has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $2.82. The stock has a market capitalization of $18.27 million, a PE ratio of 3.60 and a beta of 1.08. AEterna Zentaris has a 1-year low of $0.81 and a 1-year high of $5.57.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.15. AEterna Zentaris had a negative net margin of 536.79% and a negative return on equity of 1,428.66%. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.20 million. Sell-side analysts predict that AEterna Zentaris will post 1.77 earnings per share for the current year.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Recommended Story: What is the Moving Average Convergence Divergence (MACD) oscillator?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.